Tcs Martin1, S Gianella1, D Franklin1, P Hsue2, D M Smith1,3. 1. Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, USA. 2. Division of Cardiology, University of California San Francisco, San Francisco, CA, USA. 3. Veterans Affairs San Diego Healthcare System, San Diego, CA, USA.
Abstract
OBJECTIVES: People living with HIV (PWH) are at elevated risk of cardiac disease compared to the general population. Methamphetamine use has been associated with structural heart disease and increased mortality from cardiovascular disease but has not been explored as a cause of cardiac disease among PWH. We sought to evaluate the association of methamphetamine use and cardiac disease among PWH. METHODS: We performed a case-control study of participant data in the HIV Neurobehavioral Research Program. Cases were defined as PWH with a history of myocardial infarction or a history of heart failure (systolic or diastolic). Covariates, including methamphetamine abuse/dependence, were assessed using multiple logistic regression. RESULTS: Among 3747 PWH, there was a history of myocardial infarction in 115 subjects (3.1%), and a history of heart failure in 41 (1.1%). Current or prior methamphetamine abuse/dependence was reported in 1036 (27.9%) and was not associated with myocardial infarction (P = 0.27) or heart failure (P = 0.84). In addition to traditional risk factors, variables associated with myocardial infarction included the presence of HIV infection (P = 0.01) and duration of HIV infection (P = 0.05). Variables associated with heart failure among PWH included older age, hypertension and myocardial infarction. CONCLUSIONS: No association between methamphetamine abuse/dependence and a diagnosis of myocardial infarction or heart failure was found among PWH. Significant covariates for myocardial infarction and heart failure included traditional risk factors, the presence of HIV infection and the duration of HIV infection, emphasizing the need for optimal traditional cardiovascular risk factor management among PWH.
OBJECTIVES:People living with HIV (PWH) are at elevated risk of cardiac disease compared to the general population. Methamphetamine use has been associated with structural heart disease and increased mortality from cardiovascular disease but has not been explored as a cause of cardiac disease among PWH. We sought to evaluate the association of methamphetamine use and cardiac disease among PWH. METHODS: We performed a case-control study of participant data in the HIV Neurobehavioral Research Program. Cases were defined as PWH with a history of myocardial infarction or a history of heart failure (systolic or diastolic). Covariates, including methamphetamine abuse/dependence, were assessed using multiple logistic regression. RESULTS: Among 3747 PWH, there was a history of myocardial infarction in 115 subjects (3.1%), and a history of heart failure in 41 (1.1%). Current or prior methamphetamine abuse/dependence was reported in 1036 (27.9%) and was not associated with myocardial infarction (P = 0.27) or heart failure (P = 0.84). In addition to traditional risk factors, variables associated with myocardial infarction included the presence of HIV infection (P = 0.01) and duration of HIV infection (P = 0.05). Variables associated with heart failure among PWH included older age, hypertension and myocardial infarction. CONCLUSIONS: No association between methamphetamine abuse/dependence and a diagnosis of myocardial infarction or heart failure was found among PWH. Significant covariates for myocardial infarction and heart failure included traditional risk factors, the presence of HIV infection and the duration of HIV infection, emphasizing the need for optimal traditional cardiovascular risk factor management among PWH.
Authors: Bryan Hartzler; Julia C Dombrowski; Heidi M Crane; Joseph J Eron; Elvin H Geng; W Christopher Mathews; Kenneth H Mayer; Richard D Moore; Michael J Mugavero; Sonia Napravnik; Benigno Rodriguez; Dennis M Donovan Journal: AIDS Behav Date: 2017-04
Authors: R K Heaton; I Grant; N Butters; D A White; D Kirson; J H Atkinson; J A McCutchan; M J Taylor; M D Kelly; R J Ellis Journal: J Int Neuropsychol Soc Date: 1995-05 Impact factor: 2.892
Authors: Raza M Alvi; Anne M Neilan; Noor Tariq; Magid Awadalla; Maryam Afshar; Dahlia Banerji; Adam Rokicki; Connor Mulligan; Virginia A Triant; Markella V Zanni; Tomas G Neilan Journal: J Am Coll Cardiol Date: 2018-07-31 Impact factor: 24.094
Authors: Stephan Schürer; Karin Klingel; Marcus Sandri; Nicolas Majunke; Christian Besler; Reinhard Kandolf; Philipp Lurz; Michael Luck; Pia Hertel; Gerhard Schuler; Axel Linke; Norman Mangner Journal: JACC Heart Fail Date: 2017-06 Impact factor: 12.035
Authors: W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport Journal: N Engl J Med Date: 2006-11-30 Impact factor: 91.245
Authors: Marta Massanella; Sara Gianella; Rachel Schrier; Jennifer M Dan; Josué Pérez-Santiago; Michelli F Oliveira; Douglas D Richman; Susan J Little; Constance A Benson; Eric S Daar; Michael P Dube; Richard H Haubrich; Davey M Smith; Sheldon R Morris Journal: Sci Rep Date: 2015-08-24 Impact factor: 4.379
Authors: Anoop S V Shah; Dominik Stelzle; Kuan Ken Lee; Eduard J Beck; Shirjel Alam; Sarah Clifford; Chris T Longenecker; Fiona Strachan; Shashwatee Bagchi; William Whiteley; Sanjay Rajagopalan; Shyamasundaran Kottilil; Harish Nair; David E Newby; David A McAllister; Nicholas L Mills Journal: Circulation Date: 2018-09-11 Impact factor: 29.690
Authors: Lewis H Kuller; Russell Tracy; Waldo Belloso; Stephane De Wit; Fraser Drummond; H Clifford Lane; Bruno Ledergerber; Jens Lundgren; Jacqueline Neuhaus; Daniel Nixon; Nicholas I Paton; James D Neaton Journal: PLoS Med Date: 2008-10-21 Impact factor: 11.069